Log in
Log in
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
Sign up
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     

HOMOLOGY MEDICINES, INC.

(FIXX)
  Report
Delayed Nasdaq  -  04:00 2022-09-28 pm EDT
1.620 USD   +1.25%
09/16Homology Medicines : Corporate Presentation - September 2022
PU
09/12Homology Medicines : Corporate Presentation - September 2022
PU
09/08Homology Medicines, Inc. : Change in Directors or Principal Officers, Financial Statements and Exhibits (form 8-K)
AQ
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisionsFunds 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
09/22/2022 09/23/2022 09/26/2022 09/27/2022 09/28/2022 Date
1.65(c) 1.55(c) 1.52(c) 1.6(c) 1.62(c) Last
110 688 159 213 140 198 134 693 243 657 Volume
-1.20% -6.06% -1.94% +5.26% +1.25% Change
More quotes
Estimated financial data (e) (USD)
Sales 2022 3,47 M - -
Net income 2022 8,68 M - -
Net cash position 2022 163 M - -
P/E ratio 2022 11,1x
Yield 2022 -
Sales 2023 4,07 M - -
Net income 2023 -115 M - -
Net cash position 2023 96,2 M - -
P/E ratio 2023 -0,89x
Yield 2023 -
Capitalization 93,0 M 93,0 M -
EV / Sales 2022 -20,2x
EV / Sales 2023 -0,78x
Nbr of Employees 224
Free-Float 90,9%
More Financials
Company
Homology Medicines, Inc. is a clinical-stage genetic medicines company focused on providing treatment for rare genetic diseases. The Company’s clinical programs include HMI-102, is an investigational gene therapy candidate in clinical development for the treatment of adult patients with phenylketonuria (PKU); HMI-103, which is an investigational gene editing candidate in clinical development for the treatment of... 
More about the company
Ratings of Homology Medicines, Inc.
Trading Rating : 
Investor Rating : 
ESG Refinitiv : 
C
More Ratings
All news about HOMOLOGY MEDICINES, INC.
09/16Homology Medicines : Corporate Presentation - September 2022
PU
09/12Homology Medicines : Corporate Presentation - September 2022
PU
09/08Homology Medicines, Inc. : Change in Directors or Principal Officers, Financial Statements..
AQ
09/06Homology Medicines Promotes Chief Scientific Officer Albert Seymour to CEO
MT
09/06Homology Medicines Appoints Albert Seymour, Ph.D., Chief Executive Officer
AQ
09/06Homology Medicines, Inc. Appoints Albert Seymour as Chief Executive Officer
CI
09/06Homology Medicines, Inc. Announces Promotion of Albert Seymour to Member of the Board o..
CI
09/01Homology Medicines : Corporate Presentation - September 2022
PU
08/31Baird Adjusts Price Target on Homology Medicines to $9 From $10, Keeps Outperform Ratin..
MT
08/16Chardan Lowers Homology Medicines' Price Target to $10 From $14, Maintains Buy Rating
MT
08/16BTIG Adjusts Price Target on Homology Medicines to $12 From $29, Reiterates Buy Rating
MT
08/15Homology Medicines : Q2 Earnings Snapshot
AQ
08/15HOMOLOGY MEDICINES, INC. Management's Discussion and Analysis of Financial Condition a..
AQ
08/15Homology Medicines Reports Second Quarter 2022 Financial Results, Recent Highlights and..
AQ
08/15Homology Medicines, Inc. Reports Earnings Results for the Second Quarter and Six Months..
CI
More news
News in other languages on HOMOLOGY MEDICINES, INC.
09/06Homology Medicines, Inc. nomme Albert Seymour au poste de directeur général
09/06Homology Medicines, Inc. annonce la promotion d'Albert Seymour au poste de membre du co..
08/15Homology Medicines, Inc. annonce ses résultats financiers pour le deuxième trimestre et..
08/11Homology Medicines annonce un candidat de thérapie génique optimisé, in vivo, pour le t..
07/05Homology Medicines annonce une publication évaluée par des pairs sur la nouvelle découv..
More news
Analyst Recommendations on HOMOLOGY MEDICINES, INC.
More recommendations
ETFs positioned on HOMOLOGY MEDICINES, INC.ETFs and Trackers with Trackinsight
ETF WeightVar. 5daysRatingGeography
IShares Micro-Cap ETF - USD0.02%-6.90%United_States
BMO MSCI Genomic Innovation Index ETF - CAD0.02%0.00%-NC
Invesco Nasdaq Biotechnology ETF - USD0.01%1.85%-United_States
IShares Nasdaq US Biotechnology (D) - USD0.01%-0.90%United_States
IShares Nasdaq US Biotechnology - USD0.01%-0.99%United_States
More ETFs positioned on HOMOLOGY MEDICINES, INC.
Chart HOMOLOGY MEDICINES, INC.
Duration : Period :
Homology Medicines, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends HOMOLOGY MEDICINES, INC.
Short TermMid-TermLong Term
TrendsBearishNeutralBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 10
Last Close Price 1,62 $
Average target price 8,78 $
Spread / Average Target 442%
EPS Revisions
Managers and Directors
Albert Seymour President, Chief Executive Officer & Director
W. Bradford Smith Chief Financial Officer, Secretary & Treasurer
Arthur O. Tzianabos Chairman
Steven H. Gillis Independent Director
Richard James Gregory Independent Director
Sector and Competitors
1st jan.Capi. (M$)
HOMOLOGY MEDICINES, INC.-55.49%93
GILEAD SCIENCES, INC.-11.95%80 128
REGENERON PHARMACEUTICALS, INC.11.70%75 415
VERTEX PHARMACEUTICALS33.16%74 991
BIONTECH SE-48.10%32 514
WUXI APPTEC CO., LTD.-40.29%28 423